Taking This Obesity Medication with Menopause Hormone Therapy May Lead to More Effective Weight Loss: Study Suggests

"These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women," said Regina Castaneda, M.D., research fellow in the Division of Endocrinology at the Mayo Clinic in Jacksonville, Fla. "Previous studies of the medication semaglutide found similar results. Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications."

Researchers conducted a real-world study using electronic health records of 120 postmenopausal women over a median follow-up of 18 months. Participants were divided into two groups: 40 women received both tirzepatide and menopause hormone therapy, while 80 received tirzepatide alone.

The study found that women in the combination therapy group lost more total body weight 17% on average compared to 14% in those using only tirzepatide. Notably, 45% of women using menopause hormone therapy achieved at least 20% total weight loss, compared to just 18% of non-users.

Reference: https://www.endocrine.org/